Chemotherapy
Gastrointestinal Cancer Refractory to Chemotherapy: A Role for Octreotide?Cascinu S. · Catalano V. · Giordani P. · Baldelli A.M. · Agostinelli R. · Catalano G.Section of Experimental Oncology, Division of Medical Oncology, Azienda Ospedaliera S. Salvatore, Pesaro, Italy
|
|
Chemotherapy 2001;47(suppl 2):127–133
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
First-Page Preview
Published online: March 12, 2001
Issue release date: 2001
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 3
ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)
For additional information: https://www.karger.com/CHE
Abstract
Although octreotide has been shown to inhibit the growth of gastrointestinal (GI) tumors in vitro and in vivo, preliminary clinical trials have reported disappointing results for this somatostatin analog in patients with GI cancers. The results of these trials probably reflect the difficulty in assessing the therapeutic potential of an agent such as octreotide in GI cancers. Thus, it is possible that treatment with octreotide could be useful in the stabilization of disease if it is associated with an improvement in survival. On the basis of these considerations five randomized trials were carried out to evaluate the therapeutic potential in patients with GI cancers. Four trials (one in patients with colorectal carcinoma and three in patients with carcinoma of the pancreas) did not show any advantage of octreotide in untreated patients; in contrast, one trial reported that octreotide prolonged survival in patients with GI cancers refractory to chemotherapy. Some clinical features of the latter study (treatment with chemotherapy, different schedules) may explain these conflicting results. Although data from randomized trials suggest that octreotide is not effective in untreated asymptomatic advanced GI cancer patients, further studies are warranted to assess the efficacy of octreotide in chemotherapy refractory patients in order to clarify the impact of octreotide in terms of not only survival but also on the patients’ quality of life.
© 2001 S. Karger AG, Basel
Related Articles:
References
-
Ahlgren JD, Mac Donald JS: Gastrointestinal Oncology, ed 3. Philadelphia, Lippincott, 1992.
- Schipper DL, Wagener DJT: Chemotherapy of gastric cancer. Anticancer Drugs 1996;7:137–149.
- Labianca R, Pessi MA, Zamparelli G: Treatment of colorectal cancer. Drugs 1997;53:593–607.
- Graziano F, Catalano G, Cascinu S: Chemotherapy for advanced pancreatic cancer: The history is changing. Tumori 1998;84:308–311.
- Cascinu S, Fedeli A, Luzi Fedeli S, Catalano G: Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5fluorouracil/leucovorin combination. J Chemother 1992;4:46–49
-
Townsend CM, Singh P, Thompson JC: Effects of gastrointestinal peptides on gastrointestinal cancer growth. Gastroenterol Clin 1989;18:777–791.
- Lahm H, Svardet L, Laurent PL, Fisher JR, Leyhan A, Givel JC, Odartchenko N: Growth regulation and co-stimulation of human colorectal cancer cell lines by insulin-like growth factors I, II and transforming growth factor α. Br J Cancer 1992;65:341–346.
- Durrant LG, Watson SA, Hall A, Morris DL: Co-stimulation of gastrointestinal tumor growth by gastrin, transforming cell growth factor alpha and insulin like growth factors and cancer. Br J Cancer 1991;63:67–70.
- Lamberts SWJ: Potential role of somatostatin analogues in the treatment of cancer. Eur J Clin Invest 1987;17:281–287.
- Sheppard MC, Shapiro B, Pimstone B, Kronhein S, Berelowitz M, Gregory M: Metabolic clearance and plasma half disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab 1979;48:50–53.
- Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland LJ: Octreotide. N Engl J Med 1996;334:246–254.
-
Reubi JC: Octreotide and nonendocrine tumours: Basic knowledge and therapeutic potential, in Scarpignato C (ed): Octreotide: From Basic Science to Clinical Medicine. Prog Basic Clin Pharmacol. Basel, Karger, 1996, vol 10, pp 246–269.
- Buscail L, Esteve JP, Saint-Laurent N: Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtype SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 1995;92:1580–1584.
- Delesque N, Buscail L, Esteve JP, Saint-Laurent N, Muller C, Weckbecker G, Bruns C, Vaysse N, Susini C: SST2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res 1997;57:956–962.
- Dy DY, Whitehead RH, Morris DL: SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer. Cancer Res 1992;52:917–923.
- Pollak MN, Polychronakos C, Guyda H: Somatomedin analogue SMS 201–995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res 1989;9:889–892.
- Baghdiguian S, Verrier B, Gerard C, Fantini J: Insulin like growth factor is an autocrine regulator of human colon cancer cell differentiation and growth. Cancer Lett 1992;62:23–33.
- Baserga R: The insulin-like growth factor I receptor: A key to tumor growth? Cancer Res 1995;55:249–252.
- Cascinu S, Del Ferro E, Grianti C, Ligi M, Ghiselli M, Foglietti G, Saba V, Lungarotti F, Catalano G: Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients. Gastroenterology 1997;113:767–772.
-
Cascinu S, Del Ferro E, Ligi M, Rocchi MBL, Castellani A, Graziano F, Ghiandoni G, Catalano G: Lack of correlation between octreotide dose and decrease of serum insulin growth factor I in advanced colorectal cancer patients. GI Cancer 1997;2:139–142.
- Stewart GJ, Connor JL, Lawson JA, Preketes A, King J, Morris DL: Octreotide reduces the kinetic index, proliferating cell nuclear antigen-maximum proliferative index, in patients with colorectal cancer. Cancer 1995;76:572–578.
- Iftikhar SY, Watson SA, Morris DL: The effect of long acting somatostatin analogue SMS 201.995 therapy on tumor kinetic measurements and serum tumor marker concentrations in primary rectal cancer. Br J Cancer 1991;63:971–974.
- Klijn JGM, Hoff AM, Planting ASTh, Verweij J, Kok T, Lamberts SWJ, Portengen H, Foekens JA: Treatment of patients with metastatic pancreatic and gastrointestinal tumors with the somatostatin analogue Sandostatin: A phase II study including endocrine effects. Br J Cancer 1990;62:627–630.
-
Mallet B, Vialettes B, Haroche S, Ecoffer P, Gastaut P, Taubert JP, Vague P: Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201–995. Diabète Métab 1992;18:438–444.
-
Cascinu S, Del Ferro E, Ligi M, Staccioli MP, Giordani P, Catalano V, Agostinelli R, Muretto P, Catalano G: Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. Cancer Invest, in press.
- Manni A: Somatostatin and growth hormone regulation in cancer. Biotherapy 1992;4:31–36.
- Schally AV: Oncological applications of somatostatin analogues. Cancer Res 1988;48:6977–6985.
- Savage AP, Calam J, Wood CB, Bloom SR: SM 201–995 treatment and advanced intestinal cancer: A pilot study. Aliment Pharmacol Ther 1987;1:133–139.
-
Smith JP, Croitorou R, Townsend CM, Thompson JC: Effects of octreotide, a long-acting somatostatin analog, on advanced colon cancer. Gastroenterology 1992;102:399.
- Ebert M, Friess H, Beger HG, Büchler MW: Role of octreotide in the treatment of pancreatic cancer. Digestion 1994;55:48–51.
- Friess H, Büchler MW, Beglinger C, Weber A, Kunz J, Fritsch K, Dennler HJ, Beger HG: Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 1993;8:540–555.
- Friess H, Büchler MW, Ebert M, Malfertheiner P, Dennler HJ, Beger HG: Treatment of advanced pancreatic cancer with high-dose octreotide. Int J Pancreatol 1993;14:290–291.
- Rosenberg L, Barkun AN, Denis MH, Pollak M: Low-dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 1995;75:23–28.
- Goldberg RM, Moertel CG, Wieand HJS, Krook JE, Schutt AJ, Veeder MH, Maillard JA, Dalton RJ: A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. Cancer 1995;76:961–966.
-
Burch PA, Block M, Wieand HS, Veeder MH, Michalak JC, Hatfield AK, Wright K: A phase III evaluation of octreotide versus chemotherapy with 5FU or 5FU/leucovorin in advanced exocrine pancreatic cancer. Proc Am Soc Clin Oncol 1995;14:488.
-
Roy A, Jacobs A, Bukowsky R, Cunningham D, Hamm J, Schlag PM, Rosen P, Francois E, Finley G, Lipton A, Bruckner H, Haller D, Conroy T, Goel R, Price P, Smith G, Mietlowski W, Linnart R, Russo D, Kay A: A phase III trial of SMS 201–995 LAR and continuous infusion 5FU in unresectable stage II, III, IV pancreatic cancer. Proc Am Soc Clin Oncol 1998;17:987.
-
Pederzoli P, Maurer U, Vollmer K, Büchler MW, Kjaeve J, Van Cutsem E, Di Carlo V, Stauder H, Bergan A, Ebert M, Kiese B, Raymond MC, Kay A: Phase III trial of SMS 201–995 LAR vs placebo in unresectable stage II, III, IV pancreatic cancer. Proc Am Soc Clin Oncol 1998;17:988.
- Cascinu S, Del Ferro E, Catalano G: A randomized trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Br J Cancer 1995;71:97–101.
- Mercadante S, Spoldi E, Caraceni A, Maddaloni S, Simonetti MT: Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med 1993;7:295–299.
Article / Publication Details
First-Page Preview
Published online: March 12, 2001
Issue release date: 2001
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 3
ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)
For additional information: https://www.karger.com/CHE
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
PubMed ID
